Galectin Therapeutics Inc.

General ticker "GALT" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $166.1M (TTM average)

Galectin Therapeutics Inc. follows the US Stock Market performance with the rate: 34.0%.

Estimated limits based on current volatility of 5.2%: low 2.29$, high 2.54$

Factors to consider:

  • Total employees count: 14 (+16.7%) as of 2023
  • Company does not operate outside North America (retrieved using AI)
  • Top business risk factors: Insufficient funding, Operational and conduct risks, Economic downturns and volatility, Labor/talent shortage/retention, Cybersecurity threats
  • Current price 11.0% below estimated low

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-12-31 to 2027-12-31

  • 2025-12-31 to 2026-12-31 estimated range: [2.75$, 8.08$]
  • 2026-12-31 to 2027-12-31 estimated range: [1.96$, 5.98$]

Financial Metrics affecting the GALT estimates:

  • Positive: with PPE of -9.5 at the end of fiscal year the price was neutral
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -8.22 <= 0.07
  • Negative: Shareholder equity ratio, % of -646.09 <= 19.49
  • Negative: negative Net income
  • Positive: Investing cash flow per share per price, % of 0 > -0.65
  • Negative: 0.73 < Interest expense per share per price, % of 2.52
  • Positive: Industry inventory ratio change (median), % of 0 <= 0
  • Positive: Inventory ratio change, % of 0 <= 0

Similar symbols

Short-term GALT quotes

Long-term GALT plot with estimates

Financial data

YTD 2024-12-31 2025-12-31
Operating Revenue $0.00MM $0.00MM
Operating Expenses $42.43MM $20.09MM
Operating Income $-42.43MM $-20.09MM
Non-Operating Income $-4.61MM $-10.75MM
Interest Expense $5.54MM $7.33MM
R&D Expense $36.57MM $14.29MM
Income(Loss) $-47.05MM $-30.84MM
Profit(Loss)* $-47.05MM $-30.84MM
Stockholders Equity $-103.07MM $-126.19MM
Assets $17.50MM $19.53MM
Operating Cash Flow $-41.77MM $-23.88MM
Financing Cash Flow $31.23MM $26.48MM
Earnings Per Share** $-0.76 $-0.48

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.